DEC 21, 2019 9:03 AM PST

Magic Mushrooms Pass First Clinical Trial Against Depression

WRITTEN BY: Annie Lennon

With the efficacy of selective serotonin reuptake inhibitors such as Prozac increasingly coming under question, the search for new pharmaceutical treatments for depression is ongoing. Now, thanks to new research, the active ingredient in “magic mushrooms”, psilocybin, is one step closer to receiving treatment status. 

In a double-blind study conducted by King’s College London and mental healthcare company Compass Pathways, researchers administered 10mg and 25mg doses of psilocybin or a placebo to 89 healthy adult volunteers. Following administration of either the drug or placebo, each participant was then given 1:1 support from a trained assisting therapist over a 6-hour session. In total, the researchers conducted 25 dosing sessions, with up to 6 participants per session. 

During and after the experiment, researchers did not encounter any “serious adverse events” nor any negative side effects on cognitive and emotional function among the volunteers. The volunteers instead reported experiencing typical psychedelic side effects including changes in sensory perception and positive mood alteration. 

With these results sustained after a 12-week follow-up period, the researchers feel that this study demonstrates the feasibility of administering psilocybin in a controlled setting to healthy participants alongside 1:1 support from a therapist. 

Dr Ekaterina Malievskaia, Chief Innovation Officer and Co-Founder of Compass Pathways said, “This study is part of our overall clinical development programme in treatment-resistant depression; we wanted to look at the safety and tolerability profile of our psilocybin, and to look at the feasibility of a model where up to six 1:1 sessions are held at the same time. We are focused on getting psilocybin therapy safely to as many patients who would benefit from it as possible.” 

Dr James Rucker, a lead investigator of the study from King’s College London said, "This is the largest controlled study of psilocybin to date. The results of the study are clinically reassuring and support the further development of psilocybin as a treatment for patients with mental health problems that haven't improved with conventional therapy, such as treatment resistant depression."

The first of two testing phases, the researchers now intend to conduct a second trial that will include over 200 patients with depression across Europe and North America. 
 

Sources: PR Newswire, CNN and The Times

 

About the Author
University College London
Annie Lennon is a writer whose work also appears in Medical News Today, Psych Central, Psychology Today, and other outlets. When she's not writing, she is COO of Xeurix, an HR startup that assesses jobfit from gamified workplace simulations.
You May Also Like
MAY 25, 2022
Neuroscience
Exploring Drug Targets in Neurodegenerative Diseases
MAY 25, 2022
Exploring Drug Targets in Neurodegenerative Diseases
Introduction Life expectancy has increased globally over the last several decades. However, longer life expectancy comes ...
JUN 11, 2022
Drug Discovery & Development
Inhaled Aerosol Vaccines More Effective than Nasal Sprays
JUN 11, 2022
Inhaled Aerosol Vaccines More Effective than Nasal Sprays
Inhaled aerosol vaccines provide more protection than nasal sprays and evoke a stronger immune response. The correspondi ...
JUN 13, 2022
Microbiology
Mucus Contains Fungus-Fighting Molecules
JUN 13, 2022
Mucus Contains Fungus-Fighting Molecules
The human body plays host to a variety of microorganisms, including fungi like Candida albicans. Some strains of Candida ...
JUN 20, 2022
Health & Medicine
In a Small Study, Experimental Immunotherapy Drug for Rectal Cancer has a High Success Rate
JUN 20, 2022
In a Small Study, Experimental Immunotherapy Drug for Rectal Cancer has a High Success Rate
The New England Journal of Medicine published results from a small study by researchers at New York’s Memorial Slo ...
JUN 27, 2022
Plants & Animals
Developing a New Approach to Rabies Vaccination
JUN 27, 2022
Developing a New Approach to Rabies Vaccination
Rabies is a viral disease that can spread through the saliva. Several kinds of animals can get rabies, including humans ...
JUN 26, 2022
Drug Discovery & Development
Acupuncture Alleviates Chronic Tension Headaches in Randomized Controlled Trial
JUN 26, 2022
Acupuncture Alleviates Chronic Tension Headaches in Randomized Controlled Trial
Results from a randomized controlled trial suggest that acupuncture may relieve symptoms of chronic tension-type headach ...
Loading Comments...